Stay updated on Pembrolizumab for Meningioma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Meningioma Clinical Trial page.

Latest updates to the Pembrolizumab for Meningioma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision of Study Documents updated from v3.3.3 to v3.3.4; this appears to be a minor administrative update with no impact on eligibility criteria, trial results, or contacts. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded a Massachusetts Locations section listing study sites (Dana-Farber Cancer Institute and Massachusetts General Hospital). Removed the separate Massachusetts Locations subsection and updated the page revision to v3.3.3.SummaryDifference0.2%

- Check56 days agoChange DetectedRevision from v3.3.1 to v3.3.2, with no visible changes to study data or page layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedPublications From PubMed description updated to say publications are automatically filled in from PubMed and may not be about the study, and the revision label updated to v3.3.1.SummaryDifference0.1%

- Check70 days agoChange DetectedRemoved the government funding notice about operating status and delays, which was previously displayed at the top of the page.SummaryDifference0.4%

- Check84 days agoChange DetectedObserved changes are non-significant, limited to metadata timestamps and minor layout adjustments; no core content, eligibility criteria, or study outcomes were altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab for Meningioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Meningioma Clinical Trial page.